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ABSTRACT
Introduction Fetal growth restriction (FGR) is a relevant 
research and clinical concern since it is related to higher 
risks of adverse outcomes at any period of life. Current 
predictive tools in pregnancy (clinical factors, ultrasound 
scan, placenta-related biomarkers) fail to identify the true 
growth-restricted fetus. However, technologies based 
on metabolomics have generated interesting findings 
and seem promising. In this systematic review, we will 
address diagnostic accuracy of metabolomics analyses in 
predicting FGR.
Methods and analysis Our primary outcome is small 
for gestational age infant, as a surrogate for FGR, defined 
as birth weight below the 10th centile by customised 
or population-based curves for gestational age. A 
detailed systematic literature search will be carried in 
electronic databases and conference abstracts, using 
the keywords ‘fetal growth retardation’, ‘metabolomics’, 
‘pregnancy’ and ‘screening’ (and their variations). We will 
include original peer-reviewed articles published from 
1998 to 2018, involving pregnancies of fetuses without 
congenital malformations; sample collection must have 
been performed before clinical recognition of growth 
impairment. If additional information is required, authors 
will be contacted. Reviews, case reports, cross-sectional 
studies, non-human research and commentaries papers 
will be excluded. Sample characteristics and the diagnostic 
accuracy data will be retrieved and analysed. If data 
allows, we will perform a meta-analysis.
Ethics and dissemination As this is a systematic review, 
no ethical approval is necessary. This protocol will be 
publicised in our institutional websites and results will be 
submitted for publication in a peer-reviewed journal.
PROSPERO registration number CRD42018089985.
InTROduCTIOn   
Fetal growth restriction (FGR) is usually 
defined as a fetus that has not reached its 
intrauterine growth potential,1 2 with no 
major congenital abnormalities1 and has also 
been named as fetal growth retardation, intra-
uterine growth restriction or retardation.3 This 
heterogeneous condition is associated with 
increased risks of stillbirth,4 5 neonatal inten-
sive care unit admission,6 neonatal mortality,5 
cognitive and behavioural impairment in 
infancy7 and chronic non-transmissible 
disease in adulthood.8 FGR is mainly diag-
nosed according to the estimated fetal weight 
in ultrasound scans below the 10th centile,2 9 
although it is anticipated that misdiagnosis 
can occur: fetuses below the 10th centile, 
but with normal outcomes (‘constitutionally’ 
small), or fetuses above the 10th centile, but 
who did not follow personal growth poten-
tial.2 In this context, antenatal recognition of 
truly restricted fetuses, that is, those at higher 
risk of morbidity and mortality in any period 
of life, followed by adequate obstetrical care, 
can improve neonatal outcomes.10 
Unfortunately, in current practice, there is 
no gold standard for FGR diagnosis. Recent 
consensus has added ultrasound criteria (eg, 
abdominal circumference, umbilical and 
uterine artery Doppler measurements) and 
lowered estimated fetal weight cut-offs (<3rd 
centile),1 to improve specificity. In these 
terms, the concept of FGR can overlap with 
that of small for gestational age (SGA), which 
includes infants with birth weight below the 
10th (or fifth, or third) centile for gender and 
gestational age.11 In fact, it is common to use 
SGA as a surrogate for FGR,6 12 13 as an indica-
tion of real intrauterine growth impairment. 
Besides that, neonatal parameters seem more 
Strengths and limitations of this study
 ► This systematic review covers a great range of 
electronic databases and will also search for grey 
literature.
 ► Two researchers will perform literature search, 
data extraction and study quality assessment inde-
pendently, and any disagreement will be resolved by 
a third reviewer.
 ► Careful statistics procedures will be performed to 
identify accuracy of metabolomics in predicting fetal 
growth restriction.
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adequate as ‘patient important outcomes’, but regret-
tably, ultrasound have still low accuracy to determine 
them.6
Since 1990s, when the thrifty phenotype theory was 
introduced,14 a huge effort has been undertaken to inves-
tigate the pathologically growth restricted fetuses and 
newborns and to enhance antenatal screening.6 Clinical 
data has been intensively studied, with conflicting risk 
factors15 16 and, in general, poor accuracy is achieved for 
identifying impaired birth weight17 or neonatal morbidity,6 
even when first,18 second13 17 or third trimester19 ultra-
sound parameters are added to prediction model. Using 
only clinical or ultrasound variables, the great majority of 
SGA babies will only be recognised after birth, by popu-
lation-based5 or customised curves.17 Biomarkers, such as 
placental growth factor (PlGF), soluble fms-like tyrosine 
kynase 1 (s-Flt-1) and alpha-fetoprotein,20 have each been 
found to show promise as aids to understanding FGR. 
However, the performance of these angiogenic factors as 
predictors of FGR has been limited (positive likelihood 
ratio, LR+, of 1.3 for PlGF and 1.4 for s-Flt-1).21 Similarly, 
placental proteins are not robust enough biomarkers 
for FGR (eg, LR+ of 3.7 for placental protein-13 in first 
trimester).22 Therefore, there is a real need for better 
methods of FGR prediction.
The disappointing evidence may be due to the multi-
factorial nature of FGR; the aetiology of the condition is 
complex and poorly defined. Moreover, placental struc-
ture and functioning, maternal and fetal metabolism 
vary during pregnancy.23 In this context, contemporary 
metabolomics approaches have identified several path-
ways and metabolic processes that may contribute to FGR, 
such as disruptions in DNA methylation,24 cellular signal-
ling,25 26 neurotransmitter precursors26 27 and energy 
generation.25 26
Despite excellent performance of some metabolites in 
predicting FGR (area under the curve, above 0.9),25 26 
these studies have shown an overall modest accuracy.21 
However, only two ‘omics’ studies were included in 
Conde-Agudelo et al21 review, and issues related to 
gestational age of sampling and delivery, or analysis 
of composite outcomes, could have introduced bias 
and confounders to metabolomics findings. In recent 
years, many authors have applied diverse metabolomics 
techniques to predict FGR, suggesting that metabolite 
biomarkers may have a role to play in disease screening. 
Thus, the main objective of this systematic review is to 
define the accuracy of metabolomics techniques for 
predicting FGR. As secondary aims, we will try to deter-
mine which metabolites are robust candidates for a 
prediction model of FGR and which chemical class they 
belong to.
METhOdS And AnAlySIS
Review question
What is the accuracy of metabolomics for predicting FGR?
Condition or domain studied
SGA infant and FGR.
Participants/population
Inclusion criteria: Original studies including pregnant 
women.
Exclusion: Congenital malformation.
Interventions/exposure
Screening for SGA/FGR with metabolomics approach. 
Biomarker analysis should have been performed on 
samples taken before clinical recognition of neonatal 
outcome.
Inclusion and exclusion criteria
Original studies (cohort or case control studies) involving 
pregnant women, as the studied population and SGA 
infant (and variations of terminology), as the outcome of 
interest, will be included in this systematic review.
The reasons for excluding studies are: (1) if they are 
Cross-sectional studies, Case Reports, Editorials, Letter 
to Editors, Commentaries, Expert Opinions, or any type 
of Reviews; (2) if they describe only experimental studies 
with animals; (3) if they show duplicate publication of 
the same data; in these cases, we will use the most recent 
publication.
Outcomes
Primary outcome
SGA infant, defined as a birth weight below the 10th 
centile according to population-based or to customised 
charts.
Secondary outcomes
Birth weight below the fifth or the third centile by popu-
lation-based or customised parameters.
literature search
The primary source of information will be these electronic 
databases: PubMed, EMBASE, Latin American and Carib-
bean Health Sciences Literature, Scientific Electronic 
Library Online, Health Technology Assessment, Database 
of Abstracts of Reviews of Effects, Aggressive Research 
Intelligence Facility, Cumulative Index of Nursing and 
Allied Health Literature, Maternity and Infant Care, 
Scopus and Web of Science. Secondary sources include 
Google Scholar, hand-held searching of the reference list 
of eligible studies, conference proceedings and contact 
with authors when necessary.
The keywords linked to the outcomes of interest will 
be combined with terms related to ‘metabolomics’ 
technique, ‘pregnancy’ and ‘screening’, using Boolean 
connectors. The same search strategy will be applied 
for each database, adapting for individual filters, main 
language, their own syntax and mechanisms of search; 
the complete search strategy is provided as online supple-
mentary material.
Considering that the term metabolome was first used 
in 1998,28 we will take into account studies published in 
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the last 20 years (1998–2018). The preliminary searches 
for this systematic review have started in February 2018. 
The search strategy will be re-run before final analysis, to 
check for recently published eligible studies. There are 
no language restrictions.
data extraction and management
All searches will be exported to a reference manager 
(EndNote). Individually, two researchers (DFBL and 
ACM) will select papers according to (1) title or abstract 
and (2) full text, that will be read only when abstracts 
are not sufficient to decide about inclusion criteria. Any 
disagreement about selected studies will be dealt by a 
third researcher (EFMJ or RTS); in these cases, only 
after majority decision (2:1 ratio) the next step will be 
performed. A fifth investigator (JGC) will revise all proce-
dures before approving the data extraction. DFBL, ACM 
and ASK will deal with the statistic procedures. JGC, PNB 
and LCK will re-examine all steps and supervise data 
interpretation.
A standardised form will be applied to extract the 
variables of interest—by two independent researchers—
which will include: authors and year of publication, 
country of participants’ enrolment, study design, defini-
tion used for FGR/SGA (customised or population-based 
charts) and outcome measured, number of affected (who 
later delivered a FGR/SGA baby) and non-affected preg-
nant women, gestational age of assessment (throughout 
pregnancy), laboratory methods and biological sample 
analysed (eg, blood, amniotic fluid). In addition, data 
regarding growth impairment suspicion in pregnancy—
such as gestational age, criteria applied for diagnosis and 
follow-up—will be retrieved once available. Researchers 
will contact authors (by electronic address) if any clarifi-
cation of data is needed. The metabolites described will 
be matched with the Human Metabolome database to 
check their characteristics.29
Strategy for data synthesis
Details about data search and selection will be presented 
as a flow diagram, according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement recommendations.30 An aggregate partici-
pant data synthesis will be performed with all included 
studies; narrative data will be analysed and structured 
according to birth weight centile (10th, 5th and 3rd) 
and curve type (population-based or customised curves). 
Additionally, the metabolites will be grouped and synthe-
sised according to their biological function and chemical 
subclass. Studies’ characteristics and risk of bias assess-
ment will be demonstrated in tables. Once possible, we 
will perform subgroup analysis according to:
 ► Which metabolomic methods were applied (gas or 
liquid chromatography coupled with mass spectrom-
etry; or proton nuclear magnetic resonance).
 ► Maternal health status before pregnancy (healthy 
ones vs women with any chronic health condition).
 ► Gestational age of first fetal growth impairment suspi-
cion (early vs late FGR).1
 ► Type of pregnancy (single vs multiple).
Depending on data availability, accuracy measures 
will be calculated and a meta-analysis will be drawn. 
Considering the quantitative nature of the metabolo-
mics approach and the expected different thresholds 
for metabolites in each study, we will try to perform the 
hierarchical summary receiver characteristic operating 
curve.31 Heterogeneity will also be assessed, through I2 
test.
Risk of bias assessment
Both investigators initially involved with literature search 
(DFBL and ACM) will assess methodological quality and 
applicability of all included studies, and they must check 
their judgements. A third researcher (EFMJ or RTS) will 
resolve any disagreement if necessary and the final deci-
sions will be made by majority. We will use the ‘Quality 
Assessment of Diagnostic Accuracy Studies’32 tool, which 
comprised four domains: patient selection, characteris-
tics of index test (metabolomics technique), the refer-
ence standard test (measurement of birth weight) and 
flow and timing of patient inclusion and follow-up. Every 
study will be labelled as ‘low’, ‘high’ or ‘unclear’ risk of 
bias for each domain. For example, there is ‘low risk of 
bias’ if the study clearly states how the metabolomics tech-
niques were performed, or which birth weight curve was 
applied to identify the SGA babies.
Regarding publication bias, we will assess the symmetry 
of funnel plots if more than ten studies are included in 
the meta-analysis.33
Potential limitations to this review
Concerning the publication bias, we expect to encounter 
more published positive results and data interpreta-
tion must take this issue in consideration. The metabo-
lomics approach is highly detailed and meticulous, has 
shown great technological advancements in recent years, 
and results from mass spectrometry and from nuclear 
magnetic resonance complement each other. Therefore, 
we acknowledge that we may find distinct metabolites in 
each study and generalisation may be challenging.
In this systematic review, we have considered SGA as 
a proxy for FGR, as other authors.6 12 13 The consensus 
for FGR diagnosis was published recently1 and past 
investigations may have used distinct terminology or 
conflicting criteria for this condition in pregnancy. Addi-
tional confounders to interpret the selected studies will 
include clinical factors potentially associated to FGR/
SGA, like parity, smoking habits and history of previous 
fetal growth impairment. These characteristics will be 
appraised during data extraction and synthesis, and 
detailed evidence will be retrieved.
Ethics and dissemination
This protocol follows the PRISMA Protocols statements.34 
A report of this systematic review will be sent to our 
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sponsors. This protocol will be electronically available 
on UNICAMP-CNPq-Gates Foundation project website 
( www. medscinet. com/ samba) and Infant Centre website 
( infantcentre. ie). Our results will be submitted to publi-
cation in peer-reviewed journal.
Patient and public involvement
Patients and or public were not involved at all in elabo-
rating this systematic review protocol.
COnCluSIOn
This systematic review will synthesise data about metabolo-
mics and FGR/SGA, a promising field for understanding 
disease pathophysiology and natural history. By high-
lighting the metabolites and chemical classes that they 
belong to, this review might present solid data to future 
research protocols, that can target the most promising 
compounds, or assess the participants in a more reliable 
gestational age, for example. A robust FGR/SGA predic-
tion assumes great importance in reproductive health 
and epidemiology, since this condition is associated with 
short and long-term adverse outcomes for the offspring.
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